

Resource Summary Report

Generated by SPARC SAWG on Sep 15, 2026

Cancer Cell Line Encyclopedia

RRID:SCR_013836

Type: Tool

Proper Citation

Cancer Cell Line Encyclopedia (RRID:SCR_013836)

Resource Information

URL: <https://www.broadinstitute.org/ccle/>

Proper Citation: Cancer Cell Line Encyclopedia (RRID:SCR_013836)

Description: A collaborative project between the Broad Institute and the Novartis Institutes for Biomedical Research and its Genomics Institute of the Novartis Research Foundation, with the goal of conducting a detailed genetic and pharmacologic characterization of a large panel of human cancer models. The CCLE also works to develop integrated computational analyses that link distinct pharmacologic vulnerabilities to genomic patterns and to translate cell line integrative genomics into cancer patient stratification. The CCLE provides public access to genomic data, analysis and visualization for about 1000 cell lines.

Abbreviations: CCLE

Resource Type: data or information resource, database, portal, project portal

Defining Citation: [DOI:10.1038/nature11003](https://doi.org/10.1038/nature11003)

Keywords: cancer, cell line, human, human cancer model, genetic, portal, database, FASEB list

Availability: Public

Resource Name: Cancer Cell Line Encyclopedia

Resource ID: SCR_013836

Alternate IDs: r3d100011819

Record Creation Time: 20220129T080318+0000

Record Last Update: 20260912T200101+0000

Ratings and Alerts

No rating or validation information has been found for Cancer Cell Line Encyclopedia.

No alerts have been found for Cancer Cell Line Encyclopedia.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 95 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Tao Y, et al. (2026) TENT5A Maintains MYC mRNA Stability to Enhance Osteosarcoma Stemness. Cancer research, 86(9), 2161.

Surmann H, et al. (2026) Prognostic influence of small leucine-rich proteoglycans on serous ovarian cancer. Journal of cancer research and clinical oncology, 152(6).

Liu H, et al. (2026) AKAP7 is a prognostic biomarker involved in immune infiltration of bladder urothelial carcinoma and correlated with ferroptosis. Discover oncology, 17(1).

Xu ZJ, et al. (2026) Comprehensive characterization of VSIR reveals dual epigenetic regulation and immune landscape across hematological malignancies. Scientific reports, 16(1).

Adhikary U, et al. (2026) Cancer Susceptibility to Stapled Oncolytic Peptides Is Dictated by Membrane Cholesterol and Inflammatory Signaling. Cancer research, 86(11), 2810.

Yuan DJ, et al. (2026) Genotype-to-Phenotype Mapping of Somatic Clonal Mosaicism via Single-Cell Co-Capture of DNA Mutations and mRNA Transcripts. Cancer discovery, 16(4), 721.

Sheth AS, et al. (2025) PLK1 Inhibition Induces Synthetic Lethality in Fanconi Anemia Pathway-Deficient Acute Myeloid Leukemia. Cancer research communications, 5(4), 648.

Wang K, et al. (2025) MCLRP: enhanced prediction of anticancer drug response through low-rank matrix completion and transcriptomic profiling. BMC biology, 24(1), 4.

Du H, et al. (2025) Super-enhancer-associated LINC00963 promotes metastasis of gastric cancer through epithelial-mesenchymal transition. PloS one, 20(9), e0332396.

Wang P, et al. (2025) Nicotinamide N-methyltransferase negatively regulates??metastasis-promoting property of cancer-associated fibroblasts in lung adenocarcinoma. Cancer communications (London, England), 45(2), 110.

Wen XM, et al. (2025) Bioinformatic characterization of STING expression in hematological malignancies reveals association with prognosis and anti-tumor immunity. Frontiers in immunology, 16, 1477100.

Mahboobnia K, et al. (2025) MicroRNA-142-3p Overcomes Drug Resistance in Hepatocellular Carcinoma by Targeting YES1 and TWF1. *International journal of molecular sciences*, 26(9).

Jiang S, et al. (2025) Significance of Gelsolin Superfamily Genes in Diagnosis, Prognosis and Immune Microenvironment Regulation for Endometrial Cancer. *Cancer medicine*, 14(4), e70584.

Castro J, et al. (2025) A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair. *Cancer research*, 85(4), 758.

Suzuki H, et al. (2025) GALNT7 Stratifies dMMR/MSI Colorectal Cancer into Distinct Molecular Subsets Associated with Prognosis and PD-L1 Expression. *Cancer research communications*, 5(9), 1530.

Wen XM, et al. (2025) FOXP1 is associated with oncogenesis and clinical outcomes in hematologic malignancies. *Frontiers in immunology*, 16, 1569641.

Zhai C, et al. (2025) MEF2A, MEF2C, and MEF2D as potential biomarkers of pancreatic cancer? *BMC cancer*, 25(1), 775.

Qiu SQ, et al. (2025) GLUT1 as a generic biomarker enables near-infrared fluorescence molecular imaging guided precise intraoperative tumor detection in breast cancer. *European journal of nuclear medicine and molecular imaging*, 52(6), 2171.

Taylor B, et al. (2024) Glioblastoma vulnerability to neddylation inhibition is dependent on PTEN status, and dysregulation of the cell cycle and DNA replication. *Neuro-oncology advances*, 6(1), vdae104.

Dodson AE, et al. (2024) Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell Lines. *Cancer research communications*, 4(12), 3084.